Tempest Therapeutics Stock (NASDAQ: TPST)

Tempest Therapeutics

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Medical,Research,Laboratory:,Portrait,Of,A,Handsome,Male,Scientist,Using

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

RHHBY

Tempest Therapeutics, Inc. - Common Stock

TPST

Tempest Therapeutics hires MTS Health to explore M&amp;A and partnerships after Roche shows limited interest in its liver cancer program.

Tempest Weighs M&amp;A, Analyst Sees A &#34;Broken Story&#34; Despite Phase 2 Liver Cancer Study Success

Alphabet.Google.Shutterstock

Pre-Market Outlook

Markets

AMBO

DBGI

ENSC

GLYC

GOOG

GOOGL

LGMK

NRDS

PLRZ

QRVO

RDDT

SHPH

SNAP

SPRO

STBX

THRY

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

cancer

Equities

Contracts

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients with unresectable hepatocellular carcinoma.

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Therapeutics Inc

Press Releases

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Earnings

Tempest Reports Year End 2024 Financial Results and  Provides Business Update

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Allakos

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

BioAtla

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CEL-SCI

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kala Bio

Kezar Life Sciences

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

OSR Holdings

Ovid Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Tenax Therapeutics

X4 Pharmaceuticals

Scotiabank

HC Wainwright & Co.

Piper Sandler

Jefferies

Ladenburg Thalmann

Comments

Tempest Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell